Patents by Inventor Bart Van Den Hazel
Bart Van Den Hazel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7524931Abstract: The present invention relates to novel full-length interferon gamma (IFNG) polypeptide variants having interferon gamma activity. The full-length interferon gamma polypeptide variants of the invention are obtained by performing selected modifications in the C-terminal part of the molecule. The full-length interferon gamma polypeptide variants of the invention are useful in therapy, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis.Type: GrantFiled: June 23, 2003Date of Patent: April 28, 2009Assignee: Maxygen Holdings Ltd.Inventors: Bart Van Den Hazel, Anne Dam Jensen, Frank Bechnygaard, Kim Vilbour Andersen
-
Patent number: 7390638Abstract: When interferon gamma (IFNG) is produced in mammalian cell lines a heterogenous population of IFNG polypeptides is obtained due to C-terminal processing of the IFNG polypeptide. Clearly, this constitutes a severe problem in that valuable polypeptide material is lost and, further, it is necessary to carry out time-consuming and cumbersome purification in order to obtain a homogenous population of active IFNG polypeptides having the desired length. It has now been found that an IFNG fragment containing 132 amino acid residues (truncated at the nucleotide level by introducing a stop-codon after the codon encoding amino acid residue no. 132) does not undergo C-terminal truncation or, at least, is not significantly C-terminally truncated. Furthermore, as the IFNG fragment containing 132 amino acid residues is active, this opens up the possibility of producing a homogenous active IFNG polypeptide in eukaryotic host cells, such as CHO cells.Type: GrantFiled: April 27, 2005Date of Patent: June 24, 2008Assignee: Maxygen Holdings, Ltd.Inventors: Bart Van Den Hazel, Anne Dam Jensen, Frank Bech Nygaard, Kim Vilbour Andersen
-
Publication number: 20060160177Abstract: Glycosylated polypeptides comprising the primary structure NH2-X-Pp-COOH, wherein X is a peptide addition comprising or contributing to a glycosylation site, and Pp is a polypeptide of interest or comprising the primary structure NH2-Px-X-Py-COOH, wherein Px is an N-terminal part of a polypeptide Pp of interest, Py is a C-terminal part of said polypeptide Pp, and X is a peptide addition comprising or contributing to a glycosylation site are provided. The glycosylated polypeptides possess improved properties as compared to the polypeptide of interest.Type: ApplicationFiled: October 15, 2004Publication date: July 20, 2006Inventors: Jens Okkels, Anne Jensen, Bart van den Hazel
-
Publication number: 20060099175Abstract: The present invention relates to novel full-length interferon gamma (IFNG) polypeptide variants having interferon gamma activity. The full-length interferon gamma polypeptide variants of the invention are obtained by performing selected modifications in the C-terminal part of the molecule. The full-length interferon gamma polypeptide variants of the invention are useful in therapy, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis.Type: ApplicationFiled: June 23, 2003Publication date: May 11, 2006Inventors: Bart Van Den Hazel, Anne Jensen, Frank Bechnygaard, Kim Andersen
-
Patent number: 6958388Abstract: When interferon gamma (IFNG) is produced in mammalian cell lines a heterogenous population of IFNG polypeptides is obtained due to C-terminal processing of the IFNG polypeptide. Clearly, this constitutes a severe problem in that valuable polypeptide material is lost and, further, it is necessary to carry out time-consuming and cumbersome purification in order to obtain a homogenous population of active IFNG polypeptides having the desired length. It has now been found that an IFNG fragment containing 132 amino acid residues (truncated at the nucleotide level by introducing a stop-codon after the codon encoding amino acid residue no. 132) does not undergo C-terminal truncation or, at least, is not significantly C-terminally truncated. Furthermore, as the IFNG fragment containing 132 amino acid residues is active, this opens up the possibility of producing a homogenous active IFNG polypeptide in eukaryotic host cells, such as CHO cells.Type: GrantFiled: July 15, 2002Date of Patent: October 25, 2005Assignee: Maxygen, ApSInventors: Bart Van Den Hazel, Anne Dam Jensen, Frank Bech. Nygaard, Kim Vilbour Andersen
-
Publication number: 20040014948Abstract: The invention relates to a single-chain oilgomeric polypeptide antagonist which binds to an extracellular ligand-binding domain of a cellular receptor of a type requiring binding of an oligomeric ligand to two or more receptor subunits to be activated, the polypeptide comprising at least two, typically structurally homologous, receptor-binding sites of which at least one is capable of binding to a ligand-binding domain of the cellular receptor and at least one is incapable of effectively binding to a ligand-binding domain of the cellular receptor, whereby the single-chain oligomeric polypeptide is capable of binding to the receptor, but incapable of activating the receptor; as well as to nucleotide sequences encoding such single-chain oligomeric polypeptides, expression vectors comprising such a nucleotide sequence, recombinant host cells comprising such a nucleotide sequence or expression vector, methods for producing the nucleotide sequences and polypeptides, pharmaceutical compositions comprising the singlType: ApplicationFiled: May 23, 2003Publication date: January 22, 2004Applicant: Maxygen ApSInventors: Torben Halkier, Hans Thalsgard Schambye, Jens Sigurd Okkels, Kim Vilbour Andersen, Torben Lauesgaard Nissen, Bobby Soni, Claus Bekker Jeppesen, Bart van den Hazel
-
Publication number: 20030133907Abstract: When interferon gamma (IFNG) is produced in mammalian cell lines a heterogenous population of IFNG polypeptides is obtained due to C-terminal processing of the IFNG polypeptide. Clearly, this constitutes a severe problem in that valuable polypeptide material is lost and, further, it is necessary to carry out time-consuming and cumbersome purification in order to obtain a homogenous population of active IFNG polypeptides having the desired length. It has now been found that an IFNG fragment containing 132 amino acid residues (truncated at the nucleotide level by introducing a stop-codon after the codon encoding amino acid residue no. 132) does not undergo C-terminal truncation or, at least, is not significantly C-terminally truncated. Furthermore, as the IFNG fragment containing 132 amino acid residues is active, this opens up the possibility of producing a homogenous active IFNG polypeptide in eukaryotic host cells, such as CHO cells.Type: ApplicationFiled: July 15, 2002Publication date: July 17, 2003Applicant: MaXygen Holdings, LtdInventors: Bart Van Den Hazel, Anne Dam Jensen, Frank Bech Nygaard, Kim Vilbour Andersen
-
Publication number: 20030036181Abstract: Glycosylated polypeptides comprising the primary structure NH2—X—Pp—COOH, wherein X is a peptide addition comprising or contributing to a glycosylation site, and Pp is a polypeptide of interest or comprising the primary structure NH2-Px—X—Py-COOH, wherein Px is an N-terminal part of a polypeptide Pp of interest, Py is a C-terminal part of said polypeptide Pp, and X is a peptide addition comprising or contributing to a glycosylation site are provided. The glycosylated polypeptides possess improved properties as compared to the polypeptide of interest.Type: ApplicationFiled: June 29, 2001Publication date: February 20, 2003Inventors: Jens Sigurd Okkels, Anne Dam Jensen, Bart van den Hazel
-
Publication number: 20020127652Abstract: Heterodimeric polypeptide conjugates exhibiting FSH activity, comprising a dimeric polypeptide comprising an FSH-&agr; subunit and an FSH-&bgr; subunit, wherein at least one of the FSH-&agr; and FSH-&bgr; subunits differs from the corresponding wildtype subunit in that at least one amino acid residue acid residue comprising an attachment group for a non-polypeptide moiety has been introduced or removed, and having at least one non-polypeptide moiety bound to an attachment group of at least one of said subunits are provided. Preferably, at least one attachment group, e.g., an N- or O-glycosylation site or an attachment site for a polymer molecule such as polyethylene glycol, has been introduced, e.g., at an N-terminal. The polypeptide conjugates exhibit improved properties, in particular an increased half-life, compared to human FSH.Type: ApplicationFiled: February 9, 2001Publication date: September 12, 2002Inventors: Hans Thalsgard Schambye, Kim Vilbour Andersen, Bart van den Hazel, Jesper Christiansen, Claus Bekker Jeppesen